Heart Test Laboratories Announces Management Changes

Colleyville, TX, July 25, 2013 --(PR.com)-- Heart Test Laboratories (“HTL”) is pleased to announce it has added new key management team members as it prepares to launch the MyoVista to the market. Andrew Simpson has been appointed Executive Chairman and Mark Hilz has been appointed CEO. They join HTL to lead the company as it transitions from a development company to a full service medical device business with manufacturing and sales operations. Mr Simpson and Mr Hilz are both investors in the company and will both serve on the HTL board.

Mr Simpson was previously the group CEO of Peel Holdings, a large private company which controls $20 billion of assets. Prior to that, he was the commercial director of a large listed company and an investment banker with Rothschild having originally qualified as a Chartered Accountant with Price Waterhouse.

Mr Hilz was previously CEO of INX, a Technology Consulting Company that was listed NASDAQ and is now part of Presidio, a $2.5 Billion Technology Infrastructure Consulting Company. Prior to that Mr Hilz founded and was CEO of PC Service Source, a Nasdaq listed technology company, that grew to over $160M in revenue with 1,100 employees in an 8 year span. Mr Hilz experience includes taking start-ups from an initial capital raise to completing successful public offerings as well as M&A transactions.

Jeff Kavy has also joined the board as a Non-Executive Director. He is an investor in HTL and is a partner in Clemens & Spencer, a Texas based law firm where he specializes in international and commercial contracts Mark Hilz, the new CEO of HTL stated, “The MyoVista is one of the most important, innovative and exciting medical devices to have been developed in recent times. We believe it is a break though product with the potential to revolutionize heart screening and contribute significantly to the early identification of cardiac health issues. Andrew and I are both delighted to have joined HTL and look forward to working with the existing team and the company’s founders to ensure the successful commercialization of the HTL’s product the MyoVista.”

About Heart Test Laboratories Inc.
Heart Test Laboratories is a US based medical technology company founded in 2008 that focuses on manufacturing devices that significantly improve screening for Coronary Arterial Disease and other cardiac based abnormalities. Heart Test Lab’s current product is the patented MyoVista™ i-ECG System. The MyoVista i-ECG system is a ground breaking device that offers significant advantages in the identification of ischemic abnormalities.

The MyoVista™ System is a portable, affordable, diagnostic device that determines the presence and level of Myocardial distress. The device is simple to use and very easy for the non-specialist to interpret, with a rapid learning curve of less than one hour and includes the standard functions of a 12 lead ECG system. The system is a noninvasive electrophysiology based device and is therefore significantly more cost-effective than other tests such as a CT scan, Nuclear Stress Test or Coronary Angiogram.